Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Decorin is a novel antagonistic ligand of the Met receptor.

Goldoni S, Humphries A, Nyström A, Sattar S, Owens RT, McQuillan DJ, Ireton K, Iozzo RV.

J Cell Biol. 2009 May 18;185(4):743-54. doi: 10.1083/jcb.200901129. Epub 2009 May 11.

2.

Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels.

Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, Iozzo RV.

J Biol Chem. 2010 Dec 31;285(53):42075-85. doi: 10.1074/jbc.M110.172841. Epub 2010 Oct 25.

3.

Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans.

Iozzo RV, Schaefer L.

FEBS J. 2010 Oct;277(19):3864-75. doi: 10.1111/j.1742-4658.2010.07797.x. Epub 2010 Aug 31. Review.

5.

Hepatocyte growth factor regulates proteoglycan synthesis in interstitial fibroblasts.

Kobayashi E, Sasamura H, Mifune M, Shimizu-Hirota R, Kuroda M, Hayashi M, Saruta T.

Kidney Int. 2003 Oct;64(4):1179-88.

6.

Decorin induces rapid secretion of thrombospondin-1 in basal breast carcinoma cells via inhibition of Ras homolog gene family, member A/Rho-associated coiled-coil containing protein kinase 1.

Neill T, Jones HR, Crane-Smith Z, Owens RT, Schaefer L, Iozzo RV.

FEBS J. 2013 May;280(10):2353-68. doi: 10.1111/febs.12148. Epub 2013 Feb 15.

7.

c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination.

Taher TE, Tjin EP, Beuling EA, Borst J, Spaargaren M, Pals ST.

J Immunol. 2002 Oct 1;169(7):3793-800.

8.

Decorin as a multivalent therapeutic agent against cancer.

Neill T, Schaefer L, Iozzo RV.

Adv Drug Deliv Rev. 2016 Feb 1;97:174-85. doi: 10.1016/j.addr.2015.10.016. Epub 2015 Oct 30. Review.

9.

Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth.

Ständer M, Naumann U, Wick W, Weller M.

Cell Tissue Res. 1999 May;296(2):221-7. Review.

PMID:
10382266
10.

Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.

Kristensen IB, Pedersen L, Rø TB, Christensen JH, Lyng MB, Rasmussen LM, Ditzel HJ, Børset M, Abildgaard N.

Eur J Haematol. 2013 Sep;91(3):196-200. doi: 10.1111/ejh.12125. Epub 2013 Jul 7.

PMID:
23607294
11.

Extracellular matrix signaling through growth factor receptors during wound healing.

Tran KT, Griffith L, Wells A.

Wound Repair Regen. 2004 May-Jun;12(3):262-8. Review.

PMID:
15225204
12.

The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met.

Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S.

Nature. 2002 Mar 14;416(6877):187-90.

PMID:
11894096
13.

Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.

Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST.

Blood. 2002 Feb 15;99(4):1405-10.

14.

Decorin is a biological ligand for the epidermal growth factor receptor.

Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I.

J Biol Chem. 1999 Feb 19;274(8):4489-92.

15.

Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways.

Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, Perry D, O'Flaherty JT, Edwards IJ.

Neoplasia. 2009 Oct;11(10):1042-53.

16.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.

Cancer Res. 2009 Oct 15;69(20):8009-16. doi: 10.1158/0008-5472.CAN-08-4889. Epub 2009 Oct 6.

17.

Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 carcinoma cells.

Patel S, Santra M, McQuillan DJ, Iozzo RV, Thomas AP.

J Biol Chem. 1998 Feb 6;273(6):3121-4.

18.

Met receptor tyrosine kinase degradation is altered in response to the leucine-rich repeat of the Listeria invasion protein internalin B.

Gao X, Lorinczi M, Hill KS, Brooks NC, Dokainish H, Ireton K, Elferink LA.

J Biol Chem. 2009 Jan 9;284(2):774-83. doi: 10.1074/jbc.M805989200. Epub 2008 Nov 6.

19.

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.

Dai Y, Siemann DW.

Mol Cancer Ther. 2010 Jun;9(6):1554-61. doi: 10.1158/1535-7163.MCT-10-0359. Epub 2010 Jun 1.

20.

Somatic mutations lead to an oncogenic deletion of met in lung cancer.

Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, Severin C, Rangell L, Schwall R, Amler L, Wickramasinghe D, Yauch R.

Cancer Res. 2006 Jan 1;66(1):283-9.

Supplemental Content

Support Center